

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fameglow Holdings Limited

亮晴控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3774)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE IN AI ANTI-AGING

This is a voluntary announcement made by Fameglow Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide the shareholders of the Company and potential investors an update on the latest business development of the Group.

THE TECHNOLOGY DEVELOPMENT AGREEMENT

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that on 15 July 2026 (after trading hours), Sohadagenso Hong Kong Limited, an indirect wholly-owned subsidiary of the Company, entered into a technology development agreement (the “**Technology Development Agreement**”) with Hongkong Sunseeker Technology Limited (“**Sunseeker**”) pursuant to which Sunseeker is engaged by the Group to leverage its core artificial intelligence (“**AI**”) models to develop an anti-aging and health management platform, which will mainly focus on integrating in-depth analysis of anti-aging and health assessment reports, the formulation of personalized anti-aging plans and precise product recommendations. Pursuant to the Technology Development Agreement, an AI anti-aging model (the “**Technology**”) will be developed by Sunseeker for the Group.

REASONS FOR AND BENEFITS OF ENTERING INTO THE TECHNOLOGY DEVELOPMENT AGREEMENT

The Group has strategically positioned itself to offer its clients comprehensive beauty and wellness solutions. The Board believes that the further integration of AI technology with the anti-aging industry represents a significant growth opportunity with immense market potential. The entering into of the Technology Development Agreement marks a pivotal step in upgrading the Group’s business model into a technology-driven, data-powered, and comprehensive anti-aging platform.

Sunseeker possesses robust capabilities in AI model development and implementation, supported by the underlying technology from a leading enterprise-level AI large model company in China. Pursuant to the Technology Development Agreement, the Technology to be developed by Sunseeker for the Group will be powered by a bespoke AI anti-aging model. By leveraging such customized AI capabilities embedded in the Technology, the

Group will then develop an AI anti-aging mobile application (the “APP”), which will be equipped to process complex health data and deliver precise, scientifically backed insights directly to users.

The Directors consider that the cooperation with Sunseeker will bring significant strategic advantages and synergies to the Group. Firstly, it enables a seamless integration of the Group’s existing offline diagnostic capabilities with online user engagement. Guided by the customized AI model, the APP will allow users to perform daily lifestyle logging and tracking, thereby providing them with continuous, dynamic, and personalized anti-aging recommendations and products tailored to their real-time biological profiles.

Secondly, with the AI capabilities of the Technology, the APP will be able to serve as a continuous digital touchpoint to strengthen customer stickiness and brand loyalty. By transforming periodic physical clinic visits into an ongoing, interactive relationship, the APP is expected to unlock substantial cross-selling opportunities, effectively matching user needs with the Group’s offline medical aesthetic services and online/offline anti-aging products, thereby maximizing customer lifetime value.

Furthermore, by combining the Group’s over 17 years of deep-rooted expertise and mature operational infrastructure in the medical aesthetic industry with the technological prowess of Sunseeker and its underlying technology provider, the Group can rapidly deploy an innovative digital anti-aging solution with optimized research and development expenditure and accelerated time-to-market. The Board expects that this initiative will strengthen the Group’s brand image, establish a first-mover advantage in the “AI + Anti-aging” sector, and create sustainable revenue streams, driving long-term value for the shareholders of the Group.

In light of the above, the Directors are of the view that the cooperation of Sunseeker are fair and reasonable and in the interests of the Company and its shareholders as a whole.

INFORMATION ON THE GROUP

The Company is an investment holding company and its subsidiaries are principally engaged in provision of beauty treatment services and sale of skincare products in Hong Kong.

INFORMATION ON SUNSEEKER

Hongkong Sunseeker Technology Limited is an enterprise-level AI transformation service provider incorporated in Hong Kong with limited liability. It is dedicated to empowering enterprises in the intelligent era by transforming traditional business capabilities into core AI competitiveness through customized model solutions. With a deep understanding of industry-specific scenarios, Sunseeker provides end-to-end AI services across various sectors, encompassing strategic planning, model training, deployment, and long-term maintenance. To date, Sunseeker has successfully delivered AI solutions to several publicly listed companies.

To the best of the Directors' knowledge, information and belief after making reasonable enquiries, Sunseeker and its ultimate beneficial owners are independent third parties of the Group and they are not connected person of the Group (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)).

The Company will make further announcements on further business development as and when appropriate in accordance with the Listing Rules.

By order of the Board
Fameglow Holdings Limited
Yip Chun Kwok Danny, MH
Chairman of the Board and Executive Director

Hong Kong, 15 July 2026

As at the date of this announcement, the Board comprises Mr. Yip Chun Kwok Danny, MH, Ms. Fu Chi Ching and Mr. Chung Cheuk Man as executive Directors and Mr. Kwok David, Mr. Chan Fong and Mr. Lee Pak Ming as independent non-executive Directors